🇺🇸 FDA
Patent

US 11957680

Pyruvate kinase activators for use in treating blood disorders

granted A61KA61K31/5025A61K31/506

Quick answer

US patent 11957680 (Pyruvate kinase activators for use in treating blood disorders) held by Agios Pharmaceuticals, Inc. expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Agios Pharmaceuticals, Inc.
Grant date
Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/5025, A61K31/506, A61K31/519, A61K45/06